Muscle weakness, myositis and scleroderma induced by durvalumab.

Immune checkpoint inhibitors (ICI) have shown a change in the prognosis of multiple malignancies, but a wide range of immune-related adverse events (irAE) can occur. We present a case of a 72-year-old Caucasian male treated with Durvalumab for epidermic lung cancer, who developed a sclerosis-like syndrome and myositis. The patient was admitted to our hospital with respiratory failure due to muscular weakness and pulmonary hypertension.